Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of agenT-797 to Treat Moderate to Severe Acute Respiratory Syndrome in COVID-19 Patients

NCT04582201 is registered in ClinicalTrials.gov with MiNK Therapeutics as lead sponsor.

NCT NCT04582201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04582201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of agenT-797 to Treat Moderate to Severe Acute Respiratory Syndrome in COVID-19 Patients
Lead sponsor
MiNK Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
September 21, 2020
Completion date
April 23, 2023
Enrollment
20 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory distress syndrome, adult